Why the study?
Do indirect and direct factor Xa inhibitors improve antithrombotic therapy compared to heparins and vitamin K antagonists for the prevention and treatment of arterial and venous thromboembolism?
Do indirect and direct factor Xa inhibitors improve antithrombotic therapy compared to heparins and vitamin K antagonists for the prevention and treatment of arterial and venous thromboembolism?
This review summarizes early clinical development and dose studies of indirect and direct factor Xa inhibitors as potential alternatives to heparins and vitamin K antagonists.
Early dose studies of factor Xa inhibitors are hypothesis-generating; leaves open comparative efficacy versus heparins and vitamin K antagonists.
Synthetic or natural indirect and synthetic direct factor Xa inhibitors with specific actions on only factor Xa are currently in clinical development. The aim of these compounds is to improve the antithrombotic therapy when compared with heparins and vitamin K antagonists, which are characterized by multiple and partially unpredictable actions. The indirect factor inhibitors have to be administered parenterally, which is in contrast to the direct inhibitors of factor Xa, which may be given orally. This review describes the results of recent dose studies of these two classes of inhibitors of blood coagulation, for the prevention and treatment of arterial and venous thromboembolism.
No takes yet. Share an insight, caveat, or question.
Job Harenberg (2008) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: